JenaValve Financing Will Enable Clinical Studies of Next-Generation TAVR Systems

August 7, 2015—JenaValve Technology, Inc. announced the completion of a $26.5 million Series C expansion round of financing that will support the company’s further growth in the development and marketing of its next-generation transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease.

The financing will enable JenaValve to execute key clinical studies required to gain European regulatory approval and complete a United States feasibility study for its new aortic valve and transfemoral delivery system.

The company’s transapical TAVR system consists of the JenaValve valve system with the Cathlete Plus delivery system. The system has received CE Mark approval for aortic valve stenosis and is also indicated for the treatment of patients with aortic valve insufficiency. JenaValve currently markets the transapical TAVR device in Europe and other selected markets worldwide.

The financing round was led by JenaValve investors RMM (Rudi Mariën) and Valiance and included participation from the existing syndicate of Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, Sunstone Capital, and VI Partners.